Floatz logo

Ocrevus

Secondary-progressive Multiple Sclerosis

State University of New York at BuffaloPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Secondary-progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Siponimod
Novartis Pharmaceuticals
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
mis416
Innate Immunotherapeutics
Phase 2BB

View all 50 →

Same molecule, other indications

Ocrevus is also rated in:

primary progressive multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
Clinically Isolated SyndromeDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →